Mavorixafor (X4P-001, AMD070) is another orally bioavailable CXCR4 antagonist that enhances CD8+ cell infiltration and decreases immunosuppressive cells in the tumor microenvironment. This evidence concerns the gene CXCR4 and neoplasm.